Model parameters
| Parameters . | Base case . | Probabilistic sensitivity analysis range . | Monte Carlo distribution . | Ref . |
|---|---|---|---|---|
| Clinical inputs | ||||
| CAR T-cell therapy | ||||
| Liso-cel infusion, % | 0.97 | 0.33-1.00 | β | 18 |
| Received optional bridging chemotherapy, % | 0.63 | 0.33-0.89 | β | 18 |
| Received B-cell aplasia treatment, % | 0.16 | 0.09-0.24 | β | 18 |
| SC | ||||
| Received autologous HSCT, % | 0.46 | 0.25-0.69 | β | 18 |
| Received third-line CAR T-cell, % | 0.52 | 0.30-0.75 | β | 18 |
| Standard mortality rate of long-term DLBCL survivals | 1.18 | 0.32-2.46 | γ | 22 |
| Utility | ||||
| Base case scenario | ||||
| EFS | 0.85 | 0.49-0.99 | β | 33 |
| PD | 0.79 | 0.45-0.97 | β | 33 |
| Disutility: treatment | 0.15 | 0.08-0.26 | β | 38 |
| Costs | ||||
| Direct costs, health care sector | ||||
| Liso-cel | ||||
| Optional bridging therapy | $7 147 | $4390-$11 503 | γ | 18,39 |
| Lymphodepleting therapy | $921 | $547-$1 595 | γ | 18,39 |
| Pretreatment (apheresis, laboratory tests, and procedure) | $2 920 | $1 553-$3 887 | γ | 40 |
| Drug acquisition cost | $410 300 | 41 | ||
| Administrative cost (professional visits and laboratory tests) | $536 | $269-$754 | γ | 40,42 |
| Inpatient and ICU | $36 114 | $19 585-$49 594 | γ | 43 |
| Follow-up costs (professional visits and laboratory tests) | $4 456 | $2 401-$6 167 | γ | 40 |
| AE management | $42 651 | $26 472-$62 235 | γ | 23,40,44 |
| B-cell aplasia treatment | $5 031 | $2 463-$6 651 | γ | 40 |
| Follow-up costs during EFS y 1 | $563 | $278-$755 | γ | 24 |
| Follow-up costs during EFS y 2 | $172 | $88-$230 | γ | 24 |
| Follow-up costs during EFS y 3-5 | $103 | $50-$147 | γ | 24 |
| Follow-up costs during EFS after y 5 | $13 | $7-$18 | γ | 24 |
| SC | ||||
| Platinum-based chemotherapy | $21 440 | $11 801-$34 694 | γ | 39 |
| Autologous HSCT | $123 450 | $47 805-$159 353 | γ | 25,26 |
| Inpatient, outpatient, and emergency visits | $4 238 | $2080-$5 558 | γ | 27 |
| AE management | $29 291 | $16 907-$44 399 | γ | 23,40,44 |
| Follow-up costs during EFS y 1 | $252 | $129-$353 | γ | 24 |
| Follow-up costs during EFS y 2 | $186 | $98-$265 | γ | 24 |
| Follow-up costs during EFS y 3-5 | $54 | $26-$74 | γ | 24 |
| Follow-up costs during EFS after y 5 | $13 | $7-$19 | γ | 24 |
| Costs associated with disease progression | $5 699 | $2 696-$7 182 | γ | 27 |
| End-of-life health care costs | $19 735 | $0-$442 900 | γ | 28 |
| Indirect cost: societal | ||||
| Informal health care | ||||
| Travel-related costs, CAR T-cell therapy (academic + community) | $5 114 | $2 665-$6 955 | γ | 29 |
| Travel-related costs, SC | $3 047 | $1 426-$5 665 | γ | 30 |
| Productivity losses related to mortality | ||||
| Median monthly wage, 55-64 y | $4 708 | $2 746-$7 243 | γ | 31 |
| Median monthly wage, 65-69 y | $4 188 | $2 313-$6 238 | γ | 31 |
| Median hourly wage, 70-72 y | $20 | $10-$27 | γ | 32 |
| Median hourly wage, 73-79 y | $17 | $8-$23 | γ | 32 |
| Median hourly wage, 80-84 y | $15 | $8-$20 | γ | 32 |
| Median hourly wage, 85+ y | $13 | $7-$18 | γ | 32 |
| Unemployment rate, 60-64 y | 0.02 | 0.01-0.04 | β | 34 |
| Unemployment rate, 65-69 y | 0.03 | 0.02-0.04 | β | 34 |
| Labor force participation rate, 55-64 y | 0.65 | 0.35-0.89 | β | 35 |
| Labor force participation rate, 65-74 y | 0.27 | 0.15-0.42 | β | 35 |
| Benefit compensation rate | 0.31 | 0.17-0.47 | β | 37 |
| Participation in babysitting, % | 0.20 | 0.11-0.32 | β | 37 |
| Participation in caring for nonhousehold, % | 0.52 | 0.27-0.75 | β | 37 |
| Participation in volunteering, % | 0.36 | 0.21-0.52 | β | 37 |
| Mean weekly hours in babysitting | 17 | 10-25 | γ | 37 |
| Mean weekly hours in caring for nonhousehold | 2 | 1-3 | γ | 37 |
| Mean weekly hours in volunteering | 3 | 2-5 | γ | 36 |
| Parameters . | Base case . | Probabilistic sensitivity analysis range . | Monte Carlo distribution . | Ref . |
|---|---|---|---|---|
| Clinical inputs | ||||
| CAR T-cell therapy | ||||
| Liso-cel infusion, % | 0.97 | 0.33-1.00 | β | 18 |
| Received optional bridging chemotherapy, % | 0.63 | 0.33-0.89 | β | 18 |
| Received B-cell aplasia treatment, % | 0.16 | 0.09-0.24 | β | 18 |
| SC | ||||
| Received autologous HSCT, % | 0.46 | 0.25-0.69 | β | 18 |
| Received third-line CAR T-cell, % | 0.52 | 0.30-0.75 | β | 18 |
| Standard mortality rate of long-term DLBCL survivals | 1.18 | 0.32-2.46 | γ | 22 |
| Utility | ||||
| Base case scenario | ||||
| EFS | 0.85 | 0.49-0.99 | β | 33 |
| PD | 0.79 | 0.45-0.97 | β | 33 |
| Disutility: treatment | 0.15 | 0.08-0.26 | β | 38 |
| Costs | ||||
| Direct costs, health care sector | ||||
| Liso-cel | ||||
| Optional bridging therapy | $7 147 | $4390-$11 503 | γ | 18,39 |
| Lymphodepleting therapy | $921 | $547-$1 595 | γ | 18,39 |
| Pretreatment (apheresis, laboratory tests, and procedure) | $2 920 | $1 553-$3 887 | γ | 40 |
| Drug acquisition cost | $410 300 | 41 | ||
| Administrative cost (professional visits and laboratory tests) | $536 | $269-$754 | γ | 40,42 |
| Inpatient and ICU | $36 114 | $19 585-$49 594 | γ | 43 |
| Follow-up costs (professional visits and laboratory tests) | $4 456 | $2 401-$6 167 | γ | 40 |
| AE management | $42 651 | $26 472-$62 235 | γ | 23,40,44 |
| B-cell aplasia treatment | $5 031 | $2 463-$6 651 | γ | 40 |
| Follow-up costs during EFS y 1 | $563 | $278-$755 | γ | 24 |
| Follow-up costs during EFS y 2 | $172 | $88-$230 | γ | 24 |
| Follow-up costs during EFS y 3-5 | $103 | $50-$147 | γ | 24 |
| Follow-up costs during EFS after y 5 | $13 | $7-$18 | γ | 24 |
| SC | ||||
| Platinum-based chemotherapy | $21 440 | $11 801-$34 694 | γ | 39 |
| Autologous HSCT | $123 450 | $47 805-$159 353 | γ | 25,26 |
| Inpatient, outpatient, and emergency visits | $4 238 | $2080-$5 558 | γ | 27 |
| AE management | $29 291 | $16 907-$44 399 | γ | 23,40,44 |
| Follow-up costs during EFS y 1 | $252 | $129-$353 | γ | 24 |
| Follow-up costs during EFS y 2 | $186 | $98-$265 | γ | 24 |
| Follow-up costs during EFS y 3-5 | $54 | $26-$74 | γ | 24 |
| Follow-up costs during EFS after y 5 | $13 | $7-$19 | γ | 24 |
| Costs associated with disease progression | $5 699 | $2 696-$7 182 | γ | 27 |
| End-of-life health care costs | $19 735 | $0-$442 900 | γ | 28 |
| Indirect cost: societal | ||||
| Informal health care | ||||
| Travel-related costs, CAR T-cell therapy (academic + community) | $5 114 | $2 665-$6 955 | γ | 29 |
| Travel-related costs, SC | $3 047 | $1 426-$5 665 | γ | 30 |
| Productivity losses related to mortality | ||||
| Median monthly wage, 55-64 y | $4 708 | $2 746-$7 243 | γ | 31 |
| Median monthly wage, 65-69 y | $4 188 | $2 313-$6 238 | γ | 31 |
| Median hourly wage, 70-72 y | $20 | $10-$27 | γ | 32 |
| Median hourly wage, 73-79 y | $17 | $8-$23 | γ | 32 |
| Median hourly wage, 80-84 y | $15 | $8-$20 | γ | 32 |
| Median hourly wage, 85+ y | $13 | $7-$18 | γ | 32 |
| Unemployment rate, 60-64 y | 0.02 | 0.01-0.04 | β | 34 |
| Unemployment rate, 65-69 y | 0.03 | 0.02-0.04 | β | 34 |
| Labor force participation rate, 55-64 y | 0.65 | 0.35-0.89 | β | 35 |
| Labor force participation rate, 65-74 y | 0.27 | 0.15-0.42 | β | 35 |
| Benefit compensation rate | 0.31 | 0.17-0.47 | β | 37 |
| Participation in babysitting, % | 0.20 | 0.11-0.32 | β | 37 |
| Participation in caring for nonhousehold, % | 0.52 | 0.27-0.75 | β | 37 |
| Participation in volunteering, % | 0.36 | 0.21-0.52 | β | 37 |
| Mean weekly hours in babysitting | 17 | 10-25 | γ | 37 |
| Mean weekly hours in caring for nonhousehold | 2 | 1-3 | γ | 37 |
| Mean weekly hours in volunteering | 3 | 2-5 | γ | 36 |
AE, adverse event; ICU, intensive care unit; Ref, reference.